A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Cognitive and Behavioural Changes in MND and ALS
When someone is diagnosed with motor neurone disease (MND), the focus understandably tends to fall on movement, muscle weakness, and gradual changes i...
Sandra Bullock Speaks Out on Late Partner’s MND Experiences
Sandra Bullock is the latest high-profile personality to speak of her experiences with MND, known as ALS or Lou Gehrig’s disease in the US, after her...
Keep Connecting with Communication Aids this Speech Pathology Week 2026
MND can affect the nerves and muscles used for communication including speaking, facial expressions, gestures, and swallowing. Approximately, 80% of p...
Top 5 Frequently Asked Questions from July 2026
Each month the MND InfoLine receives a wide range of enquiries from people living with MND, their families, and health professionals. We have rounded...